[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.191.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
January 2019

Patch Testing and Allergen-Specific Inhibition in a Patient Taking Dupilumab

Author Affiliations
  • 1Department of Dermatology, School of Medicine, University of California, Irvine, Irvine
  • 2Department of Dermatology, University of California, San Francisco, San Francisco
JAMA Dermatol. 2019;155(1):120-121. doi:10.1001/jamadermatol.2018.4098

Positive patch test findings after the initiation of dupilumab therapy, an interleukin-4α receptor inhibitor used for moderate-to-severe or recalcitrant atopic dermatitis (AD), have recently been reported,1,2 suggesting that the allergic contact dermatitis (ACD) pathway is not inhibited by dupilumab. We present a case that suggests that the response to dupilumab therapy may be nuanced and that there may be an allergen-specific response.

×